

**Supplementary Table 1.** 8 years probability of OS, PFS and CI of CCyR in the 94 patients treated with imatinib as first line therapy at the Royal Liverpool University Hospital (validation sample) according to the BCR-ABL1 transcript level at 3 (higher or lower than 9.8%) and 6 (higher or lower than 1.67%) months.

<b>Transcript ratio</b>		<b>n (%)</b>	<b>OS</b>	<b>PFS</b>	<b>CI of CCyR</b>
<b>3 months</b>	<b>6 months</b>		<b>p=0.01</b>	<b>p=0.009</b>	<b>p&lt;0.001</b>
<b>&lt;9.8%</b>	<b>&lt;1.67%</b>	45 (47.9)	97.7	97.7	100
<b>&lt;9.8%</b>	<b>&gt;1.67%</b>	9 (9.6)	100	100	100
<b>&gt;9.8%</b>	<b>&lt;1.67%</b>	6 (6.4)	100	70.4	82.8
<b>&gt;9.8%</b>	<b>&gt;1.67%</b>	34 (36.2)	72.6	66.3	17.4